Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease
NCT02855476 · View on ClinicalTrials.gov ↗
Study Summary
HDClarity will seek at least 2500 research participants at different stages of Huntington's disease (HD). The primary objective is to collect a high quality CSF sample for evaluation of biomarkers and pathways that will enable the development of novel treatments for HD. The secondary objective is to generate a high quality plasma sample collection matching the CSF collections, which will also be used to evaluate biomarkers and pathways of relevance to HD research and development.
Conditions Studied
Study Locations (20)
Other
- Centre Hospitalier Universitaire d'Angers — Angers
- Le Centre Hospitalier Universitaire de Bordeaux — Bordeaux
- St Josef And Elisabeth Hospital — Bochum
- University Hospital of Erlangen — Erlangen
- George Huntington Institute — Münster
- Kbo-Isar-Amper-Klinikum Taufkirchen (Vils) — Taufkirchen
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta — Milan
- Lega Italiana Ricera Huntington — Rome
Ontario
- The Ottawa Hospital — Ottawa
- North York General Hospital — Toronto
- Centre for Movement Disorders — Toronto
Colorado
- Cenexel — Englewood
District of Columbia
- Georgetown University — Washington D.C.
Maryland
- John Hopkins University — Baltimore
North Carolina
- Wake Forest University — Winston-Salem
Tennessee
- Vanderbilt University Medical Center — Nashville
Texas
- University of Texas Health Science Center — Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,500 participants |
| Start Date | 2017-01-01 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02855476
The ClinicalTrials.gov registry entry for NCT02855476 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 2,500 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University College, London, which has 6 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Huntington's Disease appearing as the primary indexed condition, and to 0 interventions. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT02855476 reports 20 study locations spanning 11 distinct geographic areas — top geographies include Other, Ontario, Colorado. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT02855476 about?
NCT02855476 is a clinical study titled "HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease". HDClarity will seek at least 2500 research participants at different stages of Huntington's disease (HD). The primary objective is to collect a high quality CSF sample for evaluation of biomarkers and pathways that will enable the development of novel treatments for HD. The secondary objective is to...
What is the current status of trial NCT02855476?
This trial is currently recruiting. The enrollment target is 2,500 participants. The study started on 2017-01-01.
What conditions does trial NCT02855476 study?
This clinical trial studies the following conditions: Huntington's Disease. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
Who is sponsoring clinical trial NCT02855476?
This trial is sponsored by University College, London, which has 6 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT02855476 being conducted?
This trial has 20 study locations across Colorado, District of Columbia, Maryland, North Carolina, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.